HealthMore in Health→
Bepirovirsen posts phase III gains in hepatitis B cure push
Key Takeaways
- Two duplicate phase III trials reported functional cure rates of 20% and 19%.
- No patients in the placebo groups achieved a functional cure.
- About 24% of treated patients were able to discontinue nucleoside analog therapy.
DE
DT Editorial Team··via medicalxpress.com